Recognition that reduced TGFβ signaling plays a role in resistance to NSAID chemoprevention should provide new avenues for the genetic analysis of potential contributors to ASA resistance in both cardiovascular protection and cancer chemoprevention. This evidence concerns the gene TGFB1 and cancer.